MedPath

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center logo
🇺🇸United States
Ownership
Private
Established
1884-01-01
Employees
10K
Market Cap
-
Website
http://www.mskcc.org

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
Advanced Myelodysplastic Syndromes
Interventions
Drug: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
First Posted Date
2008-03-06
Last Posted Date
2021-09-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
64
Registration Number
NCT00629798
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Sensory Morbidity Following Breast Surgery

Completed
Conditions
Breast Cancer
Interventions
Behavioral: questionnaires
First Posted Date
2008-02-29
Last Posted Date
2014-01-16
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
290
Registration Number
NCT00625924
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Expressive Writing and Adjustment to Metastatic Breast Cancer

Completed
Conditions
Metastatic Breast Cancer
Interventions
Behavioral: Writing Intervention
First Posted Date
2008-02-26
Last Posted Date
2015-10-30
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
98
Registration Number
NCT00624156
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

Phase 1
Completed
Conditions
Leukemia
Myelodysplastic Syndrome
Interventions
Biological: WT1-sensitized T cells
First Posted Date
2008-02-21
Last Posted Date
2021-03-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
22
Registration Number
NCT00620633
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

Completed
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Biological: the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,
First Posted Date
2008-02-21
Last Posted Date
2013-10-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
17
Registration Number
NCT00620139
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.

Early Phase 1
Completed
Conditions
Ovarian Cancer
First Posted Date
2008-02-21
Last Posted Date
2012-01-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
9
Registration Number
NCT00620243
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

Not Applicable
Completed
Conditions
Breast Cancer
Adenocarcinoma of the Breast
Interventions
Drug: epirubicin, cyclophosphamide, Paclitaxel,
First Posted Date
2008-02-18
Last Posted Date
2015-12-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
38
Registration Number
NCT00617370
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Differential Risks for Melanoma: p16 and DNA Repair

Completed
Conditions
Skin Melanoma
Melanoma
Interventions
Other: self-administered questionnaire and blood draw
Other: health questionnaire, blood draw and skin exam
First Posted Date
2008-02-14
Last Posted Date
2011-04-20
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
323
Registration Number
NCT00615095
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer

Not Applicable
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2008-02-14
Last Posted Date
2017-03-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
38
Registration Number
NCT00615901
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States

🇺🇸

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 2 locations

Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population

Completed
Conditions
Cancer
Pulmonary Embolism
Interventions
Procedure: CT pulmonary angiogram and d-dimer draw
First Posted Date
2008-02-14
Last Posted Date
2012-01-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
213
Registration Number
NCT00615147
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath